- TNAX Biopharma has formed a strategic collaboration with Chime Biologics to develop TNAX103, a humanised anti-CD300A monoclonal antibody.
- The partnership marks Chime Biologics’ first project in Japan and will use its biologics development platform and CDMO capabilities to advance TNAX103 toward clinical readiness.
TNAX Biopharma has entered into a strategic collaboration with Chime Biologics to support the development of TNAX103, a humanised anti-CD300A monoclonal antibody. The companies described the partnership as a milestone that establishes Chime Biologics’ first project in Japan and reflects growing engagement between Japanese innovators and China’s biopharma development ecosystem.
The project centres on TNAX103, which is designed to promote efferocytosis and suppress inflammation. According to the announcement, the antibody targets mechanisms associated with ischaemia-reperfusion injury in acute kidney injury, a condition with an estimated mortality rate of around 50 per cent. TNAX Biopharma reported that preclinical data also show activity in models of stroke and spinal cord injury, and noted potential applicability in chronic inflammatory and autoimmune diseases.
Chime Biologics will apply its biologics development platform, global quality systems and rapid development capabilities to advance TNAX103 toward clinical readiness. TNAX Biopharma CEO Tak Mukohira said the partnership will support global development of the programme, describing Chime Biologics as a partner with “exceptional CMC expertise”. Dr Ichimaro Yamada added that the collaboration is expected to accelerate progress for TNAX103.
Chime Biologics CEO Dr Jimmy Wei said the agreement demonstrates recognition of its platform by Japanese innovators. He stated that connecting Japan’s discovery capabilities with China’s development infrastructure could reshape biopharma collaboration across the Asia-Pacific region.
The companies said the partnership establishes a model for integrating discovery and development capabilities across borders and reflects a broader trend in regional biopharma innovation.
